# Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

> **NCT02441062** · PHASE2 · COMPLETED · sponsor: **Sue O'Dorisio** · enrollment: 122 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Carcinoid Tumors
- Neuroblastoma
- Medulloblastoma

## Interventions

- **DRUG:** 68Ga-DOTATOC PET/CT

## Key facts

- **NCT ID:** NCT02441062
- **Lead sponsor:** Sue O'Dorisio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2020-01-20
- **Final completion:** 2020-01-20
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2020-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02441062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02441062, "Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02441062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*